SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Amneal Pharmaceuticals, Inc. (AMRX) and Encourages Long-Term AMRX Investors to Contact the Firm

Philadelphia, Pennsylvania--(Newsfile Corp. - January 29, 2024) - Kaskela Law LLC announces that it is investigating Amneal Pharmaceuticals, Inc. (NYSE: AMRX) ("Amneal") on behalf of the Company's long-term investors.

Since March 2019, shares of Amneal's common stock have declined in value from over $14.00 per share to a current trading price of below $6.00 per share, a cumulative decline of over 57% in value.

The investigation seeks to determine whether Amneal and/or the company's representatives violated the securities laws by issuing false and misleading statements and/or by failing to disclose material information to the company's investors.

Amneal shareholders are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq. or Adrienne Bell, Esq.) at (484) 229 - 0750, or by email (skaskela@kaskelalaw.com / abell@kaskelalaw.com) or online at https://kaskelalaw.com/cases/amneal-pharmaceuticals/ , for additional information about this investigation and their legal rights and options.

Kaskela Law LLC exclusively represents investors in securities fraud, corporate governance, and merger & acquisition litigation. For additional information about Kaskela Law LLC please visit www.kaskelalaw.com.

CONTACT:

KASKELA LAW LLC
D. Seamus Kaskela, Esq.
Adrienne Bell, Esq.
18 Campus Blvd., Suite 100
Newtown Square, PA 19073
(888) 715 - 1740
(484) 229 - 0750
www.kaskelalaw.com

This notice may constitute attorney advertising in certain jurisdictions.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/195964